Hepatitis B, as one of the common infectious diseases worldwide, has long troubled the medical community and patients. Although a variety of treatments are available, achieving functional cure of hepatitis B has always been the focus and difficulty of medical research. Recently, according to a report by "Liver Time", Haobo Pharmaceutical has made breakthrough progress in the treatment of hepatitis B through its independently developed ASO therapy AHB-137. Clinical trial data shows that the HBsAg negative conversion rate of AHB-137 exceeds 60%. It provides new hope for the treatment of hepatitis B.

AHB-137 is carefully developed by Haobo Pharmaceutical through its unique scientific research platform Med-Oligo™. This ASO (antisense oligonucleotide) drug has shown remarkable results in clinical trials for the treatment of hepatitis B. According to public data, among patients with baseline HBsAg levels of 100-3000IU/ml, after 12 weeks of treatment, 62% and 43% of patients in the 300 mg dose group and 225 mg dose group of AHB-137 achieved HBsAg negative conversion, respectively. This data is not only much higher than other similar drugs, but also one of the best historical data among hepatitis B treatment drugs.

In contrast, although Bepirovirsen, the ASO therapy developed by GlaxoSmithKline, also showed certain efficacy in phase 2b clinical trials, its HBsAg negative conversion rate was only 18% and 19% at 12 weeks of treatment, and 24% after 24 weeks of treatment. Weekly hours are 26% and 29%. Although the inclusion criteria of the two drugs may be slightly different, the efficacy of AHB-137 is obviously more prominent. The mechanism of action of ASO drugs is mainly to combat hepatitis B by inhibiting key steps in the virus replication process. AHB-137 not only effectively reduces HBsAg levels, but also maintains a good safety profile, which is particularly important for patients on long-term treatment. The treatment of hepatitis B not only needs to focus on short-term efficacy, but also needs to consider the long-term safety of the drug and patient tolerance. AHB-137 has shown good potential in this regard and provides strong support for the functional cure of hepatitis B.

It is worth noting that the treatment of hepatitis B is a complex process, and a single drug is often difficult to achieve a complete cure. Therefore, the future development of AHB-137 may also require combined use with other drugs or treatments to improve the overall efficacy and patient quality of life. In addition, although AHB-137 has achieved encouraging results in clinical trials, its efficacy and safety still require further verification and observation in more clinical trials. Haobo Pharmaceutical is a company jointly invested by multiple investment institutions. According to public information, Haobo Pharmaceuticals successfully received US$37 million in Series A financing from investors including InnoPinnacle Fund (initiated and established by Innovent Biologics), Yuansheng Venture Capital, Hankang Capital, Qiming Venture Partners and Yuansheng Capital .

According to information on the official website, Haobo Pharmaceutical focuses on the cure of hepatitis B and has made important contributions to promoting changes in the field of hepatitis B treatment through its cutting-edge oligonucleotide technology and efficient and precise targeted delivery platform. The success of AHB-137 not only brings new hope to hepatitis B patients, but also injects new vitality into the development of the pharmaceutical industry. In summary, Haobo Pharmaceutical's ASO therapy AHB-137 has made significant progress in the treatment of hepatitis B. Its HBsAg negative conversion rate exceeds 60%, providing a powerful tool for the functional cure of hepatitis B. However, the treatment of hepatitis B is still a long-term and complex process that requires the joint efforts of the medical community and patients to continue exploration and innovation. We look forward to AHB-137 achieving more impressive results in future clinical applications and bringing better therapeutic effects and quality of life to hepatitis B patients.

https://mp.weixin.qq.com/